Cellular leiomyoma (CL) represents an uncommon variant of uterine leiomyoma with limited data concerning its immunohistochemical and molecular profile. We performed a comprehensive analysis of 52 CL cases all of which were analyzed immunohistochemically. Molecular analysis was possible in 32 cases with sufficient DNA, and 38 cases with sufficient RNA. The immunohistochemical results showed a high expression of smooth muscle markers (calponin (100%), desmin (100%), smooth muscle actin (98.1%), caldesmon (96.1%), transgelin (96.1%), smooth muscle myosin heavy chain (86.5%), and smoothelin (61.5%)). Concerning markers of endometrial stromal differentiation, the expression of CD10 was observed in 65.4% cases (42.2% with H-score > 50), and IFITM1 in 36.5% cases (1.9% with H-score > 50). 36.5% showed HMGA2 overexpression at the IHC level, associated with increased mRNA expression in 14/14 cases. The rearrangement of the HMGA2 gene was detected in 13.2%. Chromosome 1p deletion was found in 19.3%, while 9.4% of tumors showed a pathogenic mutation in the MED12 gene. In conclusion, CL is immunohistochemically characterized by a high expression of "smooth muscle" markers commonly associated with a co-expression of "endometrial stromal" markers, where IFITM1 shows superior performance compared to CD10 regarding its specificity for differentiation from endometrial stromal tumors. The sensitivity of smoothelin in CL seems rather low, but no data is available to assess its specificity. On a molecular level, the most common mutually exclusive aberration in CL affects HMGA2, followed by chromosome 1p deletions and MED12 mutations.

Department of Obstetrics and Gynecology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Institute of Medical Biochemistry and Laboratory Diagnostics 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Institute of Pathology 1st Faculty of Medicine Charles University and General University Hospital Prague Studničkova 2 12800 Prague 2 Czech Republic

The Fingerland Department of Pathology Faculty of Medicine in Hradec Králové University Hospital in Hradec Králové Charles University Hradec Králové Czech Republic

Zobrazit více v PubMed

Oliva E et al (1995) Cellular benign mesenchymal tumors of the uterus. A comparative morphologic and immunohistochemical analysis of 33 highly cellular leiomyomas and six endometrial stromal nodules, two frequently confused tumors. Am J Surg Pathol 19(7):757–68 PubMed

Roy S, Saroha V, Jain D (2010) Highly cellular leiomyoma mimics a malignant small round-cell tumor: a diagnostic dilemma on frozen sections. Taiwan J Obstet Gynecol 49(2):203–205 PubMed

Agoff SN et al (2001) Immunohistochemical distinction of endometrial stromal sarcoma and cellular leiomyoma. Appl Immunohistochem Mol Morphol 9(2):164–169 PubMed

Oliva E (2014) Cellular mesenchymal tumors of the uterus: a review emphasizing recent observations. Int J Gynecol Pathol 33(4):374–384 PubMed

Pujani M et al (2015) Cellular leiomyoma versus endometrial stromal tumor: a pathologists’ dilemma. J Midlife Health 6(1):31–34 PubMed PMC

Mehine M et al (2014) Genomics of uterine leiomyomas: insights from high-throughput sequencing. Fertil Steril 102(3):621–629 PubMed

Mehine M et al (2016) Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers. Proc Natl Acad Sci U S A 113(5):1315–1320 PubMed PMC

Mehine, M., et al., 3'RNA Sequencing accurately classifies formalin-fixed paraffin-embedded uterine leiomyomas. Cancers (Basel), 2020. 12(12).

Markowski DN et al (2012) MED12 mutations in uterine fibroids–their relationship to cytogenetic subgroups. Int J Cancer 131(7):1528–1536 PubMed

Gregova M et al (2020) Leiomyoma with bizarre nuclei: a study of 108 cases focusing on clinicopathological features, morphology, and fumarate hydratase alterations. Pathol Oncol Res 26(3):1527–1537 PubMed

Reyes C et al (2014) Uterine smooth muscle tumors with features suggesting fumarate hydratase aberration: detailed morphologic analysis and correlation with S-(2-succino)-cysteine immunohistochemistry. Mod Pathol 27(7):1020–1027 PubMed

Zhang, Q., et al., Fumarate hydratase mutations and alterations in leiomyoma with bizarre nuclei. Int J Gynecol Pathol, 2017.

Bertsch E et al (2014) MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma. Mod Pathol 27(8):1144–1153 PubMed PMC

Ticha I et al (2019) A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants. Sci Rep 9(1):17050 PubMed PMC

Hojny J et al (2020) Identification of novel HNF1B mRNA splicing variants and their qualitative and semi-quantitative profile in selected healthy and tumour tissues. Sci Rep 10(1):6958 PubMed PMC

Carithers LJ et al (2015) A Novel Approach to High-Quality Postmortem Tissue Procurement: The GTEx Project. Biopreserv Biobank 13(5):311–319 PubMed PMC

Chu PG et al (2001) Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Mod Pathol 14(5):465–471 PubMed

McCluggage WG, Sumathi VP, Maxwell P (2001) CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology 39(3):273–278 PubMed

Nucci MR et al (2001) h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors. Am J Surg Pathol 25(4):455–463 PubMed

Oliva E et al (2002) An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol 26(4):403–412 PubMed

Parra-Herran CE et al (2014) Targeted development of specific biomarkers of endometrial stromal cell differentiation using bioinformatics: the IFITM1 model. Mod Pathol 27(4):569–579 PubMed

Rush DS et al (2001) h-Caldesmon, a novel smooth muscle-specific antibody, distinguishes between cellular leiomyoma and endometrial stromal sarcoma. Am J Surg Pathol 25(2):253–258 PubMed

Zhu XQ et al (2004) Immunohistochemical markers in differential diagnosis of endometrial stromal sarcoma and cellular leiomyoma. Gynecol Oncol 92(1):71–79 PubMed

Allen MM et al (2015) An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas. Int J Clin Exp Pathol 8(3):2795–2801 PubMed PMC

Zhai YL et al (1999) Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol 18(1):20–28 PubMed

Zhang Q et al (2018) The selected biomarker analysis in 5 types of uterine smooth muscle tumors. Hum Pathol 76:17–27 PubMed

Hodgson, A., et al., Gene fusions characterize a subset of uterine cellular leiomyomas. Genes Chromosomes Cancer, 2020.

Dundr P et al (2021) The value of immunohistochemical methods in diagnosing mesenchymal tumours of the uterus. Cesk Patol 57(2):86–95 PubMed

Rothmund R et al (2013) Clinical and pathological characteristics, pathological reevaluation and recurrence patterns of cellular leiomyomas: a retrospective study in 76 patients. Eur J Obstet Gynecol Reprod Biol 171(2):358–361 PubMed

Gisser SD, Young I (1977) Neurilemoma-like uterine myomas: an ultrastructural reaffirmation of their non-Schwannian nature. Am J Obstet Gynecol 129(4):389–392 PubMed

Lee MW et al (2002) Palisaded and verocay body prominent leiomyoma of deep soft tissue. J Dermatol 29(3):160–163 PubMed

Ali RH, Rouzbahman M (2015) Endometrial stromal tumours revisited: an update based on the 2014 WHO classification. J Clin Pathol 68(5):325–332 PubMed

Dionigi A et al (2002) Endometrial stromal nodules and endometrial stromal tumors with limited infiltration: a clinicopathologic study of 50 cases. Am J Surg Pathol 26(5):567–581 PubMed

Busca, A., et al., IFITM1 outperforms CD10 in differentiating low-grade endometrial stromal sarcomas from smooth muscle neoplasms of the uterus. Int J Gynecol Pathol, 2017.

Makinen N et al (2013) MED12 exon 2 mutations in histopathological uterine leiomyoma variants. Eur J Hum Genet 21(11):1300–1303 PubMed PMC

Makinen N et al (2017) Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors. Mol Cancer 16(1):101 PubMed PMC

Äyräväinen A et al (2020) Systematic molecular and clinical analysis of uterine leiomyomas from fertile-aged women undergoing myomectomy. Hum Reprod 35(10):2237–2244 PubMed

Matsubara A et al (2013) Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours. Histopathology 62(4):657–661 PubMed

Makinen N et al (2011) MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 334(6053):252–255 PubMed

George JW et al (2019) Integrated epigenome, exome, and transcriptome analyses reveal molecular subtypes and homeotic transformation in uterine fibroids. Cell Rep 29(12):4069-4085.e6 PubMed PMC

Velagaleti GV et al (2010) Fusion of HMGA2 to COG5 in uterine leiomyoma. Cancer Genet Cytogenet 202(1):11–16 PubMed

Mehine M et al (2013) Characterization of uterine leiomyomas by whole-genome sequencing. N Engl J Med 369(1):43–53 PubMed

Quade BJ et al (2003) Fusion transcripts involving HMGA2 are not a common molecular mechanism in uterine leiomyomata with rearrangements in 12q15. Cancer Res 63(6):1351–1358 PubMed

Lehtonen R et al (2004) Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol 164(1):17–22 PubMed PMC

Joseph NM et al (2015) Morphology and immunohistochemistry for 2SC and FH aid in detection of fumarate hydratase gene aberrations in uterine leiomyomas from young patients. Am J Surg Pathol 39(11):1529–1539 PubMed

Barker KT et al (2002) Low frequency of somatic mutations in the FH/multiple cutaneous leiomyomatosis gene in sporadic leiomyosarcomas and uterine leiomyomas. Br J Cancer 87(4):446–448 PubMed PMC

Christacos NC et al (2006) Uterine leiomyomata with deletions of Ip represent a distinct cytogenetic subgroup associated with unusual histologic features. Genes Chromosomes Cancer 45(3):304–312 PubMed

Hodge JC et al (2014) Uterine cellular leiomyomata with chromosome 1p deletions represent a distinct entity. Am J Obstet Gynecol 210(6):572.e1–7

Galindo LJ et al (2018) HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas. Gynecol Oncol 150(3):562–568 PubMed

Davidson B, Micci F (2017) Molecular characteristics of uterine sarcomas. Expert Rev Mol Diagn 17(5):515–522 PubMed

Sreekantaiah C et al (1991) An endometrial stromal sarcoma with clonal cytogenetic abnormalities. Cancer Genet Cytogenet 55(2):163–166 PubMed

Micci F et al (2016) Cytogenetic and molecular profile of endometrial stromal sarcoma. Genes Chromosomes Cancer 55(11):834–846 PubMed PMC

Micci F et al (2014) MEAF6/PHF1 is a recurrent gene fusion in endometrial stromal sarcoma. Cancer Lett 347(1):75–78 PubMed

Miettinen M et al (2019) New fusion sarcomas: histopathology and clinical significance of selected entities. Hum Pathol 86:57–65 PubMed PMC

Koontz JI et al (2001) Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci U S A 98(11):6348–6353 PubMed PMC

Mansor, S., et al., ZC3H7B-BCOR-Rearranged endometrial stromal sarcomas: a distinct subset merits its own classification? Int J Gynecol Pathol, 2018.

Ondic, O., et al., ZC3H7B-BCOR high-grade endometrial stromal sarcoma may present as myoma nascens with cytoplasmic signet ring cell change. Virchows Arch, 2020.

Micci F et al (2006) Consistent rearrangement of chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in endometrial stromal sarcoma. Cancer Res 66(1):107–112 PubMed

Panagopoulos I et al (2013) Fusion of the ZC3H7B and BCOR genes in endometrial stromal sarcomas carrying an X;22-translocation. Genes Chromosomes Cancer 52(7):610–618 PubMed

Dewaele B et al (2014) Identification of a novel, recurrent MBTD1-CXorf67 fusion in low-grade endometrial stromal sarcoma. Int J Cancer 134(5):1112–1122 PubMed

Hoang L, Chiang S, Lee CH (2018) Endometrial stromal sarcomas and related neoplasms: new developments and diagnostic considerations. Pathology 50(2):162–177 PubMed

Immunohistochemical analysis of 147 cases of low-grade endometrial stromal sarcoma: refining the immunohistochemical profile of LG-ESS on a large, molecularly confirmed series

Uterine sarcoma with KAT6B/A::KANSL1 fusion: a molecular and clinicopathological study on 9 cases

Uterine leiomyoma with RAD51B::NUDT3 fusion: a report of 2 cases

A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations

Clear cell stromal tumor of the lung with multinucleated giant cells: a report of a case with YAP1-TFE3 fusion

The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance

Epithelioid sarcoma with retained INI1 expression as a cause of a chronic leg ulcer

Desmoplastic Small Round Cell Tumor of the Uterus: A Report of Molecularly Confirmed Case with EWSR1-WT1 Fusion